Literature DB >> 32617563

The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study.

Lingyi Li1,2, Na Lu1, Ana Michelle Avina-Galindo3, Yufei Zheng1, Diane Lacaille1,4, John M Esdaile1,4, Hyon K Choi1,5, J Antonio Aviña-Zubieta1,4.   

Abstract

OBJECTIVES: To estimate the overall risk of venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) among patients newly diagnosed with RA compared with the general population without RA; and to estimate the risk trends of VTE, PE and DVT after RA diagnosis up to 5 years compared with the general population.
METHODS: Using previously validated RA case definition, we conducted a matched cohort study using the population-based administrative health database from the province of British Columbia, Canada. We calculated incidence rates (IRs) and fully adjusted hazard ratios (HRs) for the risk of VTE, DVT and PE after RA index date.
RESULTS: Among 39 142 incident RA patients (66% female, mean age 60), 1432, 543 and 1068 developed VTE, PE and DVT, respectively. IRs for the RA cohort were 3.79, 1.43 and 2.82 per 1000 person-years vs 2.70, 1.03 and 1.94 per 1000 person-years for the non-RA cohort. After adjusting for VTE risk factors, the HRs (95% CI) were 1.28 (1.20, 1.36), 1.25 (1.13, 1.39) and 1.30 (1.21, 1.40) for VTE, PE and DVT, respectively. The fully adjusted HRs for VTE during the first five years after RA diagnosis were 1.60, 1.47, 1.40, 1.30 and 1.28, respectively. A similar trend was shown in PE.
CONCLUSION: This population-based study demonstrates that RA patients have an increased risk of VTE, PE and DVT after diagnosis compared with the general population. This risk is independent of traditional VTE risk factors and is highest during the first year after RA diagnosis, then progressively declined.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  population-based; rheumatoid arthritis; risk factors; venous thromboembolism

Mesh:

Year:  2021        PMID: 32617563      PMCID: PMC7785304          DOI: 10.1093/rheumatology/keaa262

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  34 in total

1.  Venous thromboembolism: a public health concern.

Authors:  Michele G Beckman; W Craig Hooper; Sara E Critchley; Thomas L Ortel
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

2.  Gaps in care for rheumatoid arthritis: a population study.

Authors:  Diane Lacaille; Aslam H Anis; Daphne P Guh; John M Esdaile
Journal:  Arthritis Rheum       Date:  2005-04-15

3.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.

Authors:  Diane Lacaille; J Antonio Avina-Zubieta; Eric C Sayre; Michal Abrahamowicz
Journal:  Ann Rheum Dis       Date:  2016-12-28       Impact factor: 19.103

Review 4.  The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis.

Authors:  Ewa Olech; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 5.  Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?

Authors:  Ian C Scott; Samantha L Hider; David L Scott
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606

6.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis.

Authors:  Daniel H Solomon; Elena Massarotti; Rajesh Garg; Jun Liu; Claire Canning; Sebastian Schneeweiss
Journal:  JAMA       Date:  2011-06-22       Impact factor: 56.272

7.  Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations.

Authors:  Kimberly P Liang; Kelly V Liang; Eric L Matteson; Robyn L McClelland; Teresa J H Christianson; Carl Turesson
Journal:  Arthritis Rheum       Date:  2006-02

Review 8.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

9.  Interpreting studies of cardiovascular mortality in rheumatoid arthritis: the importance of timing.

Authors:  Michael M Ward
Journal:  Arthritis Rheum       Date:  2008-12-15

10.  Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom.

Authors:  Consuelo Huerta; Saga Johansson; Mari-Ann Wallander; Luis A García Rodríguez
Journal:  Arch Intern Med       Date:  2007-05-14
View more
  5 in total

1.  All-cause and cause-specific mortality in systemic lupus erythematosus: a population-based study.

Authors:  Bahar Moghaddam; Shelby Marozoff; Lingyi Li; Eric C Sayre; J Antonio Aviña- Zubieta
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

Review 2.  Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.

Authors:  Shunsuke Mori; Fumihiko Ogata; Ryusuke Tsunoda
Journal:  Clin Rheumatol       Date:  2021-09-23       Impact factor: 2.980

Review 3.  A Useful Blood Flow Restriction Training Risk Stratification for Exercise and Rehabilitation.

Authors:  Dahan da Cunha Nascimento; Nicholas Rolnick; Ivo Vieira de Sousa Neto; Richard Severin; Fabiani Lage Rodrigues Beal
Journal:  Front Physiol       Date:  2022-03-11       Impact factor: 4.566

Review 4.  A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Authors:  Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor
Journal:  Adv Ther       Date:  2022-09-05       Impact factor: 4.070

5.  Predicting Venous Thrombosis in Osteoarthritis Using a Machine Learning Algorithm: A Population-Based Cohort Study.

Authors:  Chao Lu; Jiayin Song; Hui Li; Wenxing Yu; Yangquan Hao; Ke Xu; Peng Xu
Journal:  J Pers Med       Date:  2022-01-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.